The estimated Net Worth of Gail M Farfel is at least 7.5 百万$ dollars as of 16 May 2022. Gail Farfel owns over 55,211 units of Zogenix Inc stock worth over 2,668,000$ and over the last 10 years he sold ZGNX stock worth over 482,086$. In addition, he makes 4,353,440$ as Executive Vice President、 Chief Development Officer at Zogenix Inc.
Gail has made over 16 trades of the Zogenix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 55,211 units of ZGNX stock worth 22,084$ on 16 May 2022.
The largest trade he's ever made was buying 55,211 units of Zogenix Inc stock on 16 May 2022 worth over 22,084$. On average, Gail trades about 5,869 units every 72 days since 2014. As of 16 May 2022 he still owns at least 100,000 units of Zogenix Inc stock.
You can see the complete history of Gail Farfel stock trades at the bottom of the page.
Dr. Gail M. Farfel Ph.D. serves as Executive Vice President, Chief Development Officer of the Company. Dr. Farfel has served as our Executive Vice President and Chief Development Officer since July 2015. From December 2012 to June 2015, Dr. Farfel was Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, establishing and overseeing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. From May 2008 until December 2012, Dr. Farfel served as President of G. Meredith Consulting LLC, a firm providing strategic consulting and support to biopharmaceutical and software development companies. Dr. Farfel was Vice President, Therapeutic Area and Head for Neuroscience Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation, where she oversaw a portfolio of products including Gilenya® for multiple sclerosis, Exelon® and the Exelon® Patch for Alzheimer’s disease and Parkinson’s disease, and the antidepressant, agomelatine. Dr. Farfel began her career in pharmaceutical drug development at Pfizer, Inc., where she worked in Clinical Development and Global Medical Affairs, directing programs through all stages of clinical development and regulatory submissions. Dr. Farfel is the author of over 50 scientific articles in the areas of neuropsychopharmacology and drug effects, and earned her Ph.D. in Neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence. Dr. Farfel also holds a Bachelor’s degree in Biochemistry from the University of Virginia.
As the Executive Vice President、 Chief Development Officer of Zogenix Inc, the total compensation of Gail Farfel at Zogenix Inc is 4,353,440$. There are 3 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of 10,346,800$.
Gail Farfel is 56, he's been the Executive Vice President、 Chief Development Officer of Zogenix Inc since 2015. There are 12 older and 10 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Gail's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.
Over the last 14 years, insiders at Zogenix Inc have traded over 5,100,850$ worth of Zogenix Inc stock and bought 57,764,538 units worth 193,451,745$ . The most active insiders traders include Advisors Llcperceptive Life...、Nicole Vitullo、Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of 13,059,406$. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth 15,000$.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: